Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,463 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01649089 | Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer | unknown | N/A | 224 | GOG FoundationNETWORK | 3 | May 3, 2024 | clinicaltrials |
| NCT06394297 | VIBE - Virtual Image Guided Brachytherapy Emulation for Locally Advanced Cervical Cancer (LACC)(VIBE) | unknown | N/A | 30 | Fundacao ChampalimaudOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06305494 | Genitourinary Syndrome of Menopause in Thai Gynecologic Cancer Survivors | unknown | — | 425 | Khon Kaen UniversityOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05989724 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 150 | Qurgen Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06253169 | HPV DNA Self-sampling in a General Practitioner's Office.(ASTRA) | unknown | — | 2,000 | Patient Organization VeronicaOTHER_GOV | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06378840 | the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer | unknown | — | 20 | RenJi HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06376604 | Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies | unknown | N/A | 30 | L-Nutra IncINDUSTRY | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05748353 | Endocrine Disruptors and Life STILe in Breast Cancer Development(STILVARCA) | unknown | — | 275 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05848648 | PPK Study Based on Quantitative Pharmacology in Patients With Pamipril | unknown | — | 50 | Qianfoshan HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06351228 | Fertility-sparing in Early-stage Cervcial Cancer: The ETERNITY Project(Eternity) | unknown | — | 400 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | unknown | Phase 1 / Phase 2 | 48 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341855 | Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer | unknown | N/A | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06103526 | Immunonutrition in ERAS Protocols in Gynecologic Oncology(NUTRIGO) | unknown | N/A | 200 | National and Kapodistrian University of AthensOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05305820 | Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy(PANO) | unknown | N/A | 36 | Dublin City UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06320418 | The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression | unknown | — | 56 | Ain Shams UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06317610 | Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids | unknown | — | 100 | Chongqing University Cancer HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06304922 | BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary | unknown | — | 45 | Assiut UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT06294886 | Vaginal Fluid Collection for Detection of Endometrial Cancer | unknown | — | 40 | Innovis LLCINDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04766320 | Study on TIL for the Treatment of r/r Gynecologic Tumors | unknown | Phase 1 | 15 | Shanghai 10th People's HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05910177 | Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06031493 | A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)(PROVIDENCE) | unknown | Phase 4 | 122 | Hospital Clinic of BarcelonaOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06279832 | Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer.(Romantic) | unknown | N/A | 1,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06277947 | Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward(GARD-HIPEC) | unknown | N/A | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06278636 | Laparoscopic Ultrasound Examination: Analysis of Feasibility(LUXA) | unknown | — | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05701735 | Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer(CECIL) | unknown | N/A | 45 | University of Santo Tomas Hospital, PhilippinesOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05728814 | DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer(DORA) | unknown | — | 100 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06273878 | From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy | unknown | — | 80 | Regina Elena Cancer InstituteOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05737797 | Non-Invasive Diagnosis of Endometrial Cancer(NIECE) | unknown | N/A | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06273501 | MRI and Magnetometer-guided Sentinel Lymph Node Detection in Vulvar Cancer(POSVUC) | unknown | N/A | 20 | Sahlgrenska University HospitalOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06263062 | Management With Fear of Cancer in Women Undergoing Colposcopy: Randomized Controlled Study | unknown | N/A | 60 | Alanya Alaaddin Keykubat UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06261879 | Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood | unknown | N/A | 300 | WomenX Biotech LimitedINDUSTRY | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06261892 | Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine | unknown | N/A | 300 | WomenX Biotech LimitedINDUSTRY | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04145388 | Family History Study on Cancer Risk | unknown | N/A | 18,623 | Kaiser PermanenteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06250686 | Exercise and Nutrition Intervention in Ovarian Cancer(BENITA) | unknown | N/A | 185 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06069648 | Effects of Decision Aids on the Participation of South Asian Women in Cervical Cancer Screening | unknown | N/A | 270 | Chinese University of Hong KongOTHER | 0 | Feb 7, 2024 | clinicaltrials |
| NCT05189028 | Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer | unknown | Phase 3 | 290 | Chuangzhen ChenOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06243185 | Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors | unknown | Phase 2 | 30 | Fengzhi FengOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241105 | Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 69 | Peking Union Medical College HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 3, 2024source: clinicaltrials